Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 vs taxane in HER2-positive advanced gastric cancer
CTR20140446Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Sep 2014; status: active.
02
Drugs
trastuzumab emtansine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20140446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140446.